R01AI166049

Genomic Consequences of Schistosome Hybridization

Hybridization between parasite species has the potential to transfer biomedically important genes across species boundaries with potential impact on host specificity, pathogenesis, and drug resistance. It is widely assumed that there is frequent ongoing hybridization between the livestock parasite Schistosoma bovis and the human parasite S. haematobium in West Africa. This has become a poster child for "One Health" approaches to disease management.

Genetic crosses between these schistosome species can be conducted in the laboratory, and multiple papers have described "hybrid" schistosomes between S. haematobium infecting humans and S. bovis infecting cattle. However, a central issue with these field studies is that single mitochondrial and ribosomal DNA markers are used to characterize parasite larvae. With this limited genomic resolution, it is unclear whether hybridization occurs frequently, whether it is rare and ancient, or if hybridization has never occurred and the discordance results from ancestral lineage sorting.

Our preliminary data are consistent with rare ancient hybridization and subsequent introgression, rather than widespread ongoing hybridization. We sequenced exomes from miracidia collected from Niger and Tanzania, revealing (a) no evidence for recent hybrids, (b) that all S. haematobium from Niger carry 5-8% of S. bovis DNA in their genome, (c) the size of introgressed S. bovis fragments indicated ancient hybridization (100-600 generations ago), and (d) that S. bovis DNA has risen to high frequency in some regions of the S. haematobium genome, suggesting adaptive introgression.

The central goal of this application is to use genome sequencing, population genomics, and experimental analyses to understand the frequency and genomic consequences of hybridization between S. haematobium and S. bovis. We have developed methods for whole genome sequencing from single parasite larvae from fecal samples or snails.

In Aim 1, we will examine 395 genome sequences of S. bovis and S. haematobium from archived parasite larvae or adult worms from 14 countries across Africa and from 10 states in Nigeria. We will use these data to critically evaluate: (a) evidence for recent (F1 or F2) hybridization, (b) to determine how many times introgression has occurred, (c) identify genome regions that are enriched or depleted in S. bovis alleles, and (d) to define geographical regions in which introgression has occurred.

In Aim 2, we will stage experimental genetic crosses between S. bovis and S. haematobium in rodents to determine genomic and phenotypic consequences of hybridization. In particular, we will determine genome regions involved in snail penetration of miracidia larvae and skin penetration of cercariae to determine the impact of hybridization on host specificity.

Finally, in Aim 3, we will examine both adult worms and eggs recovered from natural schistosome infections of West Africa rodents to determine whether rare hybridization events may occur. The results will address fundamental and applied questions concerning species boundaries, hybridization, host specificity, and introgression in a biomedically important and experimentally tractable parasite species.

Texas Biomedical Research Institute

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

San Antonio, Texas 782275302 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 409% from $613,689 to $3,122,895.